Clinical trials: Cushing Disease
Cushing's Disease
An Open-label, Multi-center, Expanded Access Study of Pasireotide s.c. in Patients With Cushing's Disease.
This study provided access to pasireotide sc in patients with Cushing's disease.and provided additional information for safety and efficacy of pasireotide s.c.
- Trial name
- SEASCAPE (NCT01582061)
- Testing
- Pasireotide sub-cutaneous
- Where
- 65 sites in United States, Brazil and 9 more
- Volunteers
- 104 people
- Sponsor
- Novartis Pharmaceuticals
Osteogenesis Imperfecta, Osteoporosis
REMS25: Study on the Use of REMS Technology in Diseases Commonly Associated With Reduced Bone Mineral Density (BMD)
This study evaluates bone mineral density (BMD) in pediatric patients aged 5-18 years with conditions negatively affecting bone health, using REMS (Radiofrequency Echographic Multi Spectrometry), a non-invasive and radiation-free…
- Conditions
- Osteogenesis Imperfecta, Osteoporosis, Hypogonadisms, Neoplasia
- Trial name
- NCT07412782
- Testing
- REMS
- Where
- Italy
- Volunteers
- 100 people
- Sponsor
- Meyer Children's Hospital IRCCS
Endocrine Disorders, Adiposity
Neuroendocrine Mechanisms in Adiposity: An Integrated Approach to the Characterization of Potential Pharmacological Novel Targets Based on Experimental and Clinical Models
The goal of this observational study is to evaluate, retrospectively and prospectively, the effect of different hormonal and neuropeptide dysfunctions on the body composition of patients suffering from hypothalamic-pituitary…
- Conditions
- Endocrine Disorders, Adiposity, Pituitary Adenoma, Cushing Syndrome
- Trial name
- NCT06326853
- Volunteers
- 200 people
- Sponsor
- IRCCS San Raffaele
Cushing's Disease
Preoperative Bexarotene Treatment for Cushing's Disease
The objective of this pilot study is to establish the safety and tolerability of short-term therapy with bexarotene in patient's with Cushing's disease, and study the clinical, biochemical, and cellular effects of a preoperative…
- Trial name
- NCT00845351
- Testing
- Bexarotene
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Virginia
Mild Autonomous Cortisol Secretion, Autonomous Cortisol Secretion (ACS)
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and…
- Trial name
- NCT07104812
- Testing
- Osilodrostat 1 MG
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Mayo Clinic
Osteoporosis in Cushing's Syndrome, Osteoporosis in Post-menopausal Women
Cushing's Osteoporosis Specificities
Osteoporosis induced by glucocorticoids excess constitutes the main cause of secondary osteoporosis. Most of data available are provided from cohort studies of patients treated by corticosteroids, affecting among 1% of…
- Trial name
- SOCS (NCT03162068)
- Testing
- Osteodensitometry and pQCT
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University Hospital, Clermont-Ferrand
Cushing's Disease, Acromegaly
Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies
The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.
- Conditions
- Cushing's Disease, Acromegaly, Neuroendocrine Tumors, Pituitary Tumors
- Trial name
- NCT01794793
- Testing
- Pasireotide, Cabergoline, Pasireotide LAR
- Where
- 94 sites in United States, Argentina and 26 more
- Volunteers
- 337 people
- Sponsor
- RECORDATI GROUP
Endogenous Cushing Syndrome
Canadian Continuation of Roll-over Study in Patients With Endogenous Cushing's Syndrome
The purpose of this study is to continue the evaluation of long-term safety of osilodrostat in 7 Canadian patients who have already received osilodrostat treatment in a previous Global Recordati-sponsored roll-over study and who…
- Trial name
- ISS-CA-2023 (NCT06131580)
- Testing
- Intervention/Treatment
- Where
- 3 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)
Acromegaly Due to Pituitary Adenoma, Cushing's Disease
PRESTO: A Phase III Randomised Controlled Trial of Dose-escalated Proton Beam Therapy Versus Standard of Care Radiotherapy for Functioning Pituitary Tumours
The goal of this clinical trial is to evaluate whether a higher dose of radiotherapy can lead to better outcomes for participants with functioning pituitary tumours.
- Conditions
- Acromegaly Due to Pituitary Adenoma, Cushing's Disease, Pituitary Adenoma
- Trial name
- PRESTO (NCT07813351)
- Testing
- Standard dose Intensity-Modulated Radiation Therapy (IMRT), Standard dose Proton Beam Therapy (PBT), Escalated dose Proton Beam Therapy (PBT)
- Volunteers
- 82 people
- Sponsor
- University College, London
Cushing Syndrome, Aldosteronism
China Adrenal Disease Registry
Epidemiologic studies have revealed a tremendous increase in the prevalence of adrenal associated disease and related mortality worldwide.
- Conditions
- Cushing Syndrome, Aldosteronism, Hypoadrenalism, Congenital Adrenal Hyperplasia
- Trial name
- CASE (NCT04890444)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Nelson Syndrome
Pasireotide Therapy in Patients With Nelson's Syndrome
Nelson's syndrome, an expanding pituitary tumour, occurs in up to 30% of adults after bilateral adrenalectomy for Cushing's disease, for which no medical treatment exists.
- Trial name
- NCT01617733
- Testing
- Pasireotide
- Where
- 4 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Cushing's Syndrome, Adrenal Incidentalomas
Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome?
Background: The evaluation for hypercortisolism includes an overnight 1mg dexamethasone (DXM) suppression test. An important shortcoming is the diagnostic specificity of only 80%, which is likely due to inter-individual…
- Conditions
- Cushing's Syndrome, Adrenal Incidentalomas, Alcoholism, Obesity
- Trial name
- DXM (NCT01504555)
- Where
- 4 sites in Norway
- Volunteers
- 300 people
- Sponsor
- Haukeland University Hospital
Hypertension, Hypercortisolemia
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Osilodrostat has proven to be a safe and efficacious treatment for patients with CS. Demonstrating normalisation of hypercortisolaemia and in patients with hypertension and/or dysglycaemia clinically relevant and statistically…
- Conditions
- Hypertension, Hypercortisolemia, Cushing Syndrome
- Trial name
- LINC CARE (NCT07247162)
- Testing
- Osilodrostat
- Volunteers
- 63 people
- Sponsor
- RECORDATI GROUP
Cushing Disease
Fimepinostat, Combination HDAC and Pi3-kinase Inhibitor Tumor-Directed Therapy for Cushing Disease
Supported by the pre-clinical data (summarized in Research Strategy), the investigators propose that Fimepinostat is an ideal candidate drug in the treatment and intervention of patients with Cushing Disease.
- Trial name
- NCT05971758
- Testing
- Fimepinostat
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Adrenal Gland Hyperfunction, Adrenal Gland Hypofunction
Dose Response Relationship for Single Doses of Corticotropin Releasing Hormone (CRH) in Normal Volunteers and in Patients With Adrenal Insufficiency
Corticotropin Releasing Hormone (CRH) is a hypothalamic hormone made up of 41 amino acids. Amino acids are proteins that when combined make up different substances, like hormones.
- Conditions
- Adrenal Gland Hyperfunction, Adrenal Gland Hypofunction, Cushing's Syndrome, Healthy
- Trial name
- NCT00001180
- Testing
- Ovine Corticotropin-Releasing Hormone (oCRH)
- Where
- United States
- Volunteers
- 2,250 people, healthy volunteers welcome
- Sponsor
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Hypercortisolism, Cushing Syndrome
Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
This retrospective, multi-center, chart review study will collect patient data from medical charts of pediatric patients who have been treated with Korlym for Cushing's syndrome.
- Trial name
- NCT03379363
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Corcept Therapeutics
Cushing Disease
Hair Cortisol and Cushing's Disease
The biochemical tools usable to assess the control of hypercortisolism in patients with Cushing's disease receiving medical treatments are debatable.
- Trial name
- HAIRCUSH (NCT04201444)
- Testing
- Patient group, Remission control group, Bilateral surrenalectomy control group
- Where
- 7 sites in France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Bordeaux
Cushing Disease
Use of [18F]FET PET-MRI to Improve Detection of Pituitary Adenomas in Cushing's Disease
In ACTH-dependent hypercortisolism it is important to distinguish between Cushing's disease (CD), with ACTH production by a pituitary neuroendocrine tumour (PitNET) and Cushing's syndrome (CS), with ectopic ACTH production.
- Trial name
- FIND (NCT07108244)
- Testing
- [18F]FET PET-MRI
- Where
- 2 sites in Netherlands, Switzerland
- Volunteers
- 43 people
- Sponsor
- University Hospital, Basel, Switzerland
Cushing's Disease, Cushing's Syndrome
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
This is a compassionate use study. In addition to providing compassionate use access to mifepristone, objectives of the study will be to evaluate the safety and utility of mifepristone in the treatment of the signs and symptoms…
- Trial name
- NCT01371565
- Testing
- Mifepristone
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Corcept Therapeutics
Hypercorticism
Patient and Partner Perception After Remission of Cushing's Syndrome
Hypercortisolism leads to long term physical and cognitive sequelae. This also holds true for quality of life, even several years after remission.
- Trial name
- CUSHING (NCT03607474)
- Testing
- Questionnaires of life quality for patients, Questionnaires of life quality for caregivers
- Where
- France
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille